ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 910

Anti-Carbamylated Protein Antibodies (Anti-CarP) Precede The Onset Of Rheumatoid Arthritis

Jing Shi1, Lotte A. van de Stadt2, E.W.Nivine Levarht1, Tom W. J. Huizinga1, Dörte Hamann3, Dirkjan van Schaardenburg4, René E.M. Toes1 and Leendert A. Trouw1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoantibodies and post-translational modification

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cells in Human and Animal Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-citrullinated protein antibodies (ACPA) and IgM-Rheumatoid Factor (IgM-RF) are auto-antibodies that can be detected many years before the clinical diagnosis of Rheumatoid Arthritis (RA) [1]. Since ACPA and IgM-RF are known as predictive and prognostic markers of RA, it is conceivable that these antibodies play a pathogenic role in RA. In recent studies we discovered anti-carbamylated protein (anti-CarP) antibodies as a prognostic marker in RA [2]. In addition anti-CarP antibodies are associated with a conversion to RA in patients that suffer from arthralgia [3]. In this study we analyzed whether anti-CarP antibodies can also be detected prior to the onset of the symptoms of RA and which auto-antibody appears first over time.

Methods:

Sera of 79 RA patients obtained prior to the onset of symptoms and 141 age and sex matched controls that were regular blood donors from Amsterdam, The Netherlands, were tested for the presence of anti-carbamylated fetal calf serum (Ca-FCS) antibodies, anti-cyclic citrullinated peptide 2 (CCP2) antibodies and RF-IgM. A median of 5 (IQR 4-6) sequential pre-RA sera, obtained at 1-6 year intervals was available for analysis.

Results:

Anti-CarP antibodies were present in 27% of the serum samples that were drawn just prior to the diagnosis of RA of blood donors compared to 4% of the matched control samples. Anti-CarP antibodies were present in both ACPA positive and ACPA negative patients. Of the 79 individuals that developed RA, 42% were positive for anti-CCP2 antibodies and 25% for IgM RF.

Analysis of the longitudinal samples revealed that anti-CarP antibodies could be detected many years before the onset of symptoms (median 5 years) (Figure 1). Comparing the first appearance of the three autoantibody families revealed that both ACPA and anti-CarP antibodies appear (similarly) earlier in time as compared to IgM-RF.

Conclusion:

Next to ACPA and IgM-RF also the newly identified anti-CarP antibodies appear many years before the onset of clinical symptoms of RA.

1. Nielen MM, et al. Arthritis Rheum. 2004; 50:380-6.

2. Shi J, et al. Proc.Natl.Acad.Sci.U.S.A 2011; 108:17372-7.

3. Shi J, et al.. Arthritis Rheum. 2013; 72(1) 148-50


Disclosure:

J. Shi,
None;

L. A. van de Stadt,
None;

E. W. N. Levarht,
None;

T. W. J. Huizinga,
None;

D. Hamann,
None;

D. van Schaardenburg,

Patent,

4;

R. E. M. Toes,
None;

L. A. Trouw,

Janssen Biologics,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-carbamylated-protein-antibodies-anti-carp-precede-the-onset-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology